Technical Analysis for CNTX - Context Therapeutics Inc.

Grade Last Price % Change Price Change
D 5.52 0.36% 0.02
CNTX closed up 0.36 percent on Tuesday, December 7, 2021, on 38 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical CNTX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 20 DMA Bullish 0.36%
Calm After Storm Range Contraction 0.36%
Stochastic Reached Oversold Weakness 0.36%
Wide Bands Range Expansion 0.36%
Oversold Stochastic Weakness 0.36%
Older End-of-Day Signals for CNTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 12 hours ago
Down 3% about 12 hours ago
Fell Below 20 DMA about 12 hours ago
Possible NR7 about 12 hours ago
20 DMA Support about 13 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Context Therapeutics Inc. Description

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Organ Systems Treatment Of Cancer Breast Cancer Antineoplastic Drugs Endocrine System Cancer Therapeutics Breast Cancers Antiprogestogens Estranes

Is CNTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.85
52 Week Low 4.38
Average Volume 5,651,768
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 5.39
10-Day Moving Average 5.66
Average True Range 1.02
ADX 21.03
+DI 38.42
-DI 19.81
Chandelier Exit (Long, 3 ATRs) 7.78
Chandelier Exit (Short, 3 ATRs) 7.45
Upper Bollinger Bands 6.65
Lower Bollinger Band 4.13
Percent B (%b) 0.55
BandWidth 46.62
MACD Line -0.10
MACD Signal Line -0.19
MACD Histogram 0.0845
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.47
Resistance 3 (R3) 6.47 6.15 6.31
Resistance 2 (R2) 6.15 5.91 6.15 6.25
Resistance 1 (R1) 5.84 5.76 5.84 5.84 6.20
Pivot Point 5.52 5.52 5.52 5.52 5.52
Support 1 (S1) 5.21 5.28 5.21 5.21 4.84
Support 2 (S2) 4.89 5.13 4.89 4.79
Support 3 (S3) 4.58 4.89 4.73
Support 4 (S4) 4.58